Avantax Advisory Services Inc. Has $315,000 Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Avantax Advisory Services Inc. cut its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 22.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,709 shares of the medical research company’s stock after selling 497 shares during the quarter. Avantax Advisory Services Inc.’s holdings in Charles River Laboratories International were worth $315,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Versant Capital Management Inc raised its position in Charles River Laboratories International by 1,071.4% in the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 150 shares during the last quarter. Pinnacle Bancorp Inc. increased its holdings in Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after purchasing an additional 65 shares in the last quarter. Tortoise Investment Management LLC grew its holdings in Charles River Laboratories International by 77.7% in the fourth quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company’s stock worth $49,000 after purchasing an additional 115 shares during the period. ORG Wealth Partners LLC acquired a new position in Charles River Laboratories International during the 4th quarter worth approximately $56,000. Finally, Wilmington Savings Fund Society FSB bought a new stake in Charles River Laboratories International during the 3rd quarter valued at $59,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Bank of America lowered their price target on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. Redburn Atlantic upgraded shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 target price for the company in a report on Monday, March 3rd. The Goldman Sachs Group downgraded shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating and cut their price target for the stock from $190.00 to $170.00 in a report on Friday, March 21st. UBS Group reiterated a “neutral” rating and set a $185.00 price target (down previously from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. Finally, Robert W. Baird lowered their price objective on Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating on the stock in a research note on Thursday, February 20th. One equities research analyst has rated the stock with a sell rating and sixteen have given a hold rating to the stock. According to MarketBeat, Charles River Laboratories International has an average rating of “Hold” and a consensus target price of $189.77.

Insider Activity

In other Charles River Laboratories International news, COO Birgit Girshick bought 1,514 shares of the business’s stock in a transaction that occurred on Thursday, February 20th. The shares were bought at an average cost of $164.63 per share, with a total value of $249,249.82. Following the completion of the purchase, the chief operating officer now directly owns 55,058 shares of the company’s stock, valued at $9,064,198.54. This trade represents a 2.83 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO James C. Foster acquired 6,075 shares of the business’s stock in a transaction dated Thursday, February 20th. The stock was acquired at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the completion of the transaction, the chief executive officer now owns 183,639 shares in the company, valued at approximately $30,302,271.39. The trade was a 3.42 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 1.30% of the company’s stock.

Charles River Laboratories International Price Performance

Shares of NYSE:CRL opened at $161.57 on Wednesday. The stock has a market cap of $8.26 billion, a P/E ratio of 1,077.13, a P/E/G ratio of 4.54 and a beta of 1.45. Charles River Laboratories International, Inc. has a 12 month low of $150.79 and a 12 month high of $273.32. The company has a 50 day moving average of $165.32 and a 200 day moving average of $183.30. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, topping the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company had revenue of $1 billion for the quarter, compared to analysts’ expectations of $983.63 million. During the same period in the prior year, the business earned $2.46 earnings per share. Charles River Laboratories International’s revenue for the quarter was down 1.1% compared to the same quarter last year. As a group, sell-side analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).